| アブストラクト | BACKGROUND: The serum biomarker cancer antigen 125 (CA125) is widely used as an investigation for possible ovarian cancer in symptomatic women presenting to primary care. However, its diagnostic performance in this setting is unknown. We evaluated the performance of CA125 in primary care for the detection of ovarian and non-ovarian cancers. METHODS AND FINDINGS: We studied women in the United Kingdom Clinical Practice Research Datalink with a CA125 test performed between 1 May 2011-31 December 2014. Ovarian and non-ovarian cancers diagnosed in the year following CA125 testing were identified from the cancer registry. Women were categorized by age: <50 years and >/=50 years. Conventional measures of test diagnostic accuracy, including sensitivity, specificity, and positive predictive value, were calculated for the standard CA125 cut-off (>/=35 U/ml). The probability of a woman having cancer at each CA125 level between 1-1,000 U/ml was estimated using logistic regression. Cancer probability was also estimated on the basis of CA125 level and age in years using logistic regression. We identified CA125 levels equating to a 3% estimated cancer probability: the "risk threshold" at which the UK National Institute for Health and Care Excellence advocates urgent specialist cancer investigation. A total of 50,780 women underwent CA125 testing; 456 (0.9%) were diagnosed with ovarian cancer and 1,321 (2.6%) with non-ovarian cancer. Of women with a CA125 level >/=35 U/ml, 3.4% aged <50 years and 15.2% aged >/=50 years had ovarian cancer. Of women with a CA125 level >/=35 U/ml who were aged >/=50 years and who did not have ovarian cancer, 20.4% were diagnosed with a non-ovarian cancer. A CA125 value of 53 U/ml equated to a 3% probability of ovarian cancer overall. This varied by age, with a value of 104 U/ml in 40-year-old women and 32 U/ml in 70-year-old women equating to a 3% probability. The main limitations of our study were that we were unable to determine why CA125 tests were performed and that our findings are based solely on UK primary care data, so caution is need in extrapolating them to other healthcare settings. CONCLUSIONS: CA125 is a useful test for ovarian cancer detection in primary care, particularly in women >/=50 years old. Clinicians should also consider non-ovarian cancers in women with high CA125 levels, especially if ovarian cancer has been excluded, in order to prevent diagnostic delay. Our results enable clinicians and patients to determine the estimated probability of ovarian cancer and all cancers at any CA125 level and age, which can be used to guide individual decisions on the need for further investigation or referral. |
|---|
| ジャーナル名 | PLoS medicine |
|---|
| Pubmed追加日 | 2020/10/29 |
|---|
| 投稿者 | Funston, Garth; Hamilton, Willie; Abel, Gary; Crosbie, Emma J; Rous, Brian; Walter, Fiona M |
|---|
| 組織名 | The Primary Care Unit, Department of Public Health and Primary Care, University;of Cambridge, Cambridge, United Kingdom.;University of Exeter, Exeter, United Kingdom.;Gynaecological Oncology Research Group, Division of Cancer Sciences, University;of Manchester, Manchester, United Kingdom.;Department of Obstetrics and Gynaecology, Manchester University NHS Foundation;Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.;National Cancer Registration and Analysis Service, Public Health England,;Cambridge, United Kingdom. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33112854/ |
|---|
